Lantern Pharma Inc. has announced the successful completion of targeted enrollment for its Phase 2 HARMONIC™ clinical trial in Japan, focusing on the treatment of non-small cell lung cancer (NSCLC) in never-smoker patients. The trial is evaluating the efficacy of LP-300 in combination with carboplatin and pemetrexed for patients whose cancer has progressed following treatment with tyrosine kinase inhibitors (TKIs). A total of 10 patients were enrolled ahead of schedule at five clinical sites, including the National Cancer Center Japan. Lantern Pharma is planning to release further clinical and outcome data from this trial later this quarter, which will cover both Asian and U.S. patient cohorts. The trial aims to address the unmet medical needs of this specific patient population.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。